Europe Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Country and Growth Forecast, 2022-2028

The Europe Cancer Gene Therapy Market is expected to witness market growth of 20.3% CAGR during the forecast period (2022-2028).

Favorable government therapeutic laws is expected to further enhance numerous prospects, resulting in the expansion of the cancer gene therapy market over the projection period. However, high treatment costs and undesired immune reactions are projected to limit the growth of the cancer gene therapy market. In addition, compared to prior years, there was an increase in novel gene therapy pipeline developments in 2020. As a result, the number of clinical trials, product launches, collaborations, and product innovations are increasing.

Over the last few years, the gene therapy market has seen a series of changes. Initially, gene therapy for monogenetic illnesses was popular; however, the market for gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by putting therapeutic DNA into their bodies.

The German cancer gene has a lot of room for growth in the coming years. One of the primary reasons driving country growth is a better regulatory environment. Over the last few years, German regulatory authorities have simplified the regulatory process, making it easier for industry participants to advertise their medicines in Germany. Furthermore, a growing interest among healthcare experts in the availability of advanced cancer gene therapy is expected to help the country prosper.

Lung cancer is caused by the uncontrollable proliferation of aberrant cells in one or both lungs. Persons who smoke have the highest risk of lung cancer, despite the fact that it can affect people who have never smoked. The time and number of cigarettes smoked by a patient increase the risk of lung cancer. Other risk factors include secondhand smoke, asbestos, certain metals, some organic compounds, radiation, air pollution, and diesel exhaust at the workplace or in the environment.

The Germany market dominated the Europe Cancer Gene Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $324.3 million by 2028. The UK market is poised to grow at a CAGR of 19.3% during (2022-2028). Additionally, The France market is expected to exhibit a CAGR of 21.2% during (2022-2028).

Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc

Scope of the Study

Market Segments Covered in the Report:

By Therapy

• Gene Induced Immunotherapy
• Oncolytic Virotherapy, and
• Gene Transfer

By End User

• Hospitals
• Diagnostic centers
• Research Institutes

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• GlaxoSmithKline PLC (GSK)
• Amgen, Inc.
• Bristol Myers Squibb Company
• Karyopharm Therapeutics, Inc.
• Gilead Sciences, Inc.
• Adaptimmune Limited
• Genelux Corporation
• Sarepta Therapeutics, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free